G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Clinical trial NCT03455270 · COMPLETED

Trial details

NCT number: NCT03455270
Sponsor: G1 Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Ductal, Breast Breast Cancer Female Breast Neoplasm Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Stage IV Breast Cancer

Start date: 2018-05-09
Primary completion: 2022-09-29
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.